Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-08-23
DOI
10.3389/fphar.2019.00944
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
- (2018) Penelope A. Bradbury et al. LUNG CANCER
- Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
- (2018) Cristina Pérez-Ramírez et al. PHARMACOGENOMICS JOURNAL
- Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
- (2018) Cong Wang et al. Frontiers in Pharmacology
- Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy
- (2017) Amrita Singh et al. MEDICAL ONCOLOGY
- Methylenetetrahydrofolate reductase tagging polymorphisms are associated with risk of non-small cell lung cancer in eastern Chinese Han population
- (2017) Hao Ding et al. Oncotarget
- A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer
- (2016) Satoshi Fukuda et al. LUNG CANCER
- Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
- (2016) Cristina Pérez-Ramírez et al. PHARMACOLOGICAL RESEARCH
- Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients
- (2016) Yunfeng Ruan et al. Scientific Reports
- Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer
- (2015) Akihiro Nishiyama et al. LUNG CANCER
- Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients
- (2015) Hye In Woo et al. PHARMACOGENOMICS
- A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer
- (2015) Ke-Jun Liu et al. Oncotarget
- Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
- (2014) Motoyasu Kato et al. BMC CANCER
- The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
- (2014) Lei Wang et al. BMC CANCER
- Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
- (2014) Paweł Krawczyk et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI
- (2014) Rong-Hang Hu et al. MEDICAL ONCOLOGY
- Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations
- (2014) A Corrigan et al. PHARMACOGENOMICS JOURNAL
- Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
- (2014) Xiaoying Li et al. TUMOR BIOLOGY
- Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
- (2013) Isamu Okamoto et al. INVESTIGATIONAL NEW DRUGS
- Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer
- (2013) Tindara Franchina et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Charles M. Rudin et al. Journal of Thoracic Oncology
- Association between TYMS Expression and Efficacy of Pemetrexed–Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- (2013) Ting Wang et al. PLoS One
- Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy
- (2013) WEN-JUAN LI et al. Oncology Letters
- Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
- (2012) Ming Li et al. PLoS One
- Biomarker analysis in a phase III study of pemetrexed–carboplatin versus etoposide–carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
- (2011) E. F. Smit et al. ANNALS OF ONCOLOGY
- Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study
- (2010) Araba A. Adjei et al. Journal of Thoracic Oncology
- SLC19A1 pharmacogenomics summary
- (2010) Sook Wah Yee et al. Pharmacogenetics and Genomics
- Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer
- (2009) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426
- (2009) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation
- (2008) Ilan Ifergan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More